Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer

SIMPLE SUMMARY: The survival of patients with metastatic colorectal cancer (mCRC) has been improved over the years and now reaches 30–40 months. However, few therapeutic options are available after failure of first- and second-line treatments. In fact, prognosis of chemo-refractory mCRC remains poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, Davide, Martini, Giulia, Famiglietti, Vincenzo, Napolitano, Stefania, De Falco, Vincenzo, Troiani, Teresa, Latiano, Tiziana Pia, Ros, Javier, Elez Fernandez, Elena, Vitiello, Pietro Paolo, Maiello, Evaristo, Ciardiello, Fortunato, Martinelli, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073594/
https://www.ncbi.nlm.nih.gov/pubmed/33920531
http://dx.doi.org/10.3390/cancers13081941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073594/
https://www.ncbi.nlm.nih.gov/pubmed/33920531
http://dx.doi.org/10.3390/cancers13081941

Ejemplares similares